Skip to main content
. Author manuscript; available in PMC: 2016 Nov 29.
Published in final edited form as: Mucosal Immunol. 2016 Jan 27;9(5):1173–1182. doi: 10.1038/mi.2015.141

Figure 6.

Figure 6

Effect of AT-1001 against lethal influenza challenge. (A) C57BL/6J mice were infected with mouse-adapted influenza strain PR8 (∼7500 TCID50, i.n.; ∼LD90). Mice received vehicle (saline; i.v.), Eritoran (E5564; 200 μg/mouse; i.v.), or AT-1001 (150 μg/mouse; i.v.) from day 2 to day 6 post-infection. Survival (A) and clinical scores (B) were monitored daily for 14 days. Data shown is combined from 3 separate experiments (5 mice/treatment group/experiment). (C) Lung wet-to-dry (W/D) weight ratio as an index for pulmonary edema after infection. C57BL/6J mice were infected and treated as described above. On day 7 post-infection, lungs were harvested and and lung weights were measured immediately after excision and recorded as wet weight. Lung tissue was air dried for 5-6 days and re-weighed until a stable dry weight obtained. The W/D weight ratio was calculated by dividing the wet by dry weight. The N for each group is indicated in each bar. Each vertical bar represents the mean (+ s.e.m.).